ClinicalTrials.gg
RecruitingNCT05986864Updated Aug 28, 2026

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

A Phase 1/2 interventional study of SKG0106 in Neovascular Age-related Macular Degeneration, sponsored by Skyline Therapeutics (US) Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Skyline Therapeutics (US) Inc. (part of Xiamen Amoytop Biotech Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
42nd of 91
68 · median 62
Started
2024
with 6 others
Phase 1/2
18 of 107
8 open now
Primary completion
2027-01
later than 25 of 42 live
Registered
69th of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 42nd largest by planned enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2024, is one of 18 in phase 1/2, reaches primary completion later than 25 of the 42 other live ones, and was the 69th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • AMD
  • wet AMD
  • wAMD
  • nAMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary and able to sign a dated ICF prior to any study-related procedures and able to complete the study as required by the protocol;
  2. Aged ≥ 50 years at screening;

    Study Eye:

  3. Diagnosis of nAMD as determined by the PI;
  4. Active CNV lesions secondary to age-related macular degeneration (AMD);
  5. Subjects must have been responsive to anti-VEGF therapy as assessed by the PI prior to study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in the study eye at baseline;
  2. Retinal pigment epithelial tear in the study eye at screening;
  3. Current vitreous hemorrhage in the study eye or history of vitreous hemorrhage within 4 weeks prior to baseline;
  4. Any condition that, in the opinion of the investigator, may limit visual acuity improvement in the study eye;
  5. History of retinal detachment or active retinal detachment in the study eye;
  6. Any prior gene therapy.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Phase I: Low dose

    SKG0106 One-Time Intraocular Injection Dose Level 1

    Genetic: SKG0106

  • Experimental
    Phase I: Medium dose

    SKG0106 One-Time Intraocular Injection Dose Level 2

    Genetic: SKG0106

  • Experimental
    Phase I: High dose

    SKG0106 One-Time Intraocular Injection Dose Level 3

    Genetic: SKG0106

Interventions

  • GeneticSKG0106

    SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

06

What researchers measure

Primary outcomes

  1. Characteristics of dose limiting toxicities (DLTs)

    Time frame: 4 Weeks

  2. Type, severity, and incidence of ocular and systemic adverse events (AEs)

    Time frame: 52 Weeks

Secondary outcomes

  1. Mean change from baseline in best corrected visual acuity (BCVA) at each visit

    BCVA of the study eye is examined by the Early Treatment of Diabetic Retinopathy Study (ETDRS) testing at screening and baseline.

    Time frame: 52 Weeks

  2. Mean change from baseline in central subfield thickness (CST) at each visit

    Spectral domain optical coherence tomography (SD-OCT) will be performed to measure CST at screening and at each visit (prior to study drug injection, if available).

    Time frame: 52 Weeks

  3. Mean change from baseline in patient-reported outcome (VFQ-25) scale score at each visit

    Both the total scale and subscale scores of the VFQ-25 is ranging from 0 to 100, and higher scores mean a better outcome.

    Time frame: 52 Weeks

07

Study locations

8 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartActual
Feb 23, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 30, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05986864
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Feb 23, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

Eddy Anglade, MD
Contact
eanglade@focusbiosciences.com
+1-908-884-1246

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion